In the present analysis of data from the ExteNET study, we evaluated PIK3CA amplifications and somatic mutations to obtain a comprehensive assessment of the prognostic and predictive significance of PIK3CA alterations in patients with early-stage HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.